GridAI Technologies Payout Ratio

What does GridAI Technologies do? First Wave BioPharma Inc develops targeted therapies for gastrointestinal diseases, focusing on non-systemic treatments. The company's primary products include adrulipase, a recombinant lipase enzyme for fat digestion in cystic fibrosis and chronic pancreatitis patients, and niclosamide, an oral small molecule with antiviral and anti-inflammatory properties. They are advancing Phase 2 clinical programs for FW-COV targeting GI infections from SARS-CoV-2 and FW-UP for ulcerative proctitis. The company serves patients with gastrointestinal conditions through clinical-stage drug development. The firm generates revenue through research and development activities, clinical trials, and potential future drug sales. Its pipeline includes two distinct drug candidates, adrulipase and niclosamide, each with specific therapeutic applications. The company targets patients requiring non-systemic treatments for GI diseases, focusing on cystic fibrosis, chronic pancreatitis, and inflammatory bowel conditions. First Wave BioPharma Inc operates as a clinical-stage biopharmaceutical company, developing its own drug candidates without external partnerships. The company's revenue streams are derived from its internal R&D efforts, with no mention of licensing, partnerships, or external sales channels in the provided description. GridAI Technologies is one of the most popular companies on Eulerpool.